Loading stock data…
Kymera Therapeutics, Inc. (KYMR)
$109.32+1.20 (+1.11%)
After Hours$109.35+0.03 (+0.03%)· Last close Jun 29
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Kymera Therapeutics, Inc. in the Healthcare sector is trading at $109.32 with a market capitalization of $6.0B. Wall Street consensus targets $123.05 (21 analysts), implying a +12.6% move over the next 12 months. The stock is currently 16% below its 52-week high of $130.05, remaining 45.0% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +12.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $34.37M↑ | $2.87M↑ | $2.76M↓ | $11.48M↓ | $22.10M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$84.15M↑ | -$97.90M↓ | -$88.67M↓ | -$84.56M↓ | -$74.43M |
| Net Income | -$69.23M↑ | -$86.98M↓ | -$82.17M↓ | -$76.61M↓ | -$65.58M |
Peer Comparison
JNJUNHPFE
Fundamentals
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.02B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.06
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-20.46%
Volume
Today's trading volume
1.68M
Recent News
Why Kymera Therapeutics Stock Popped This Week
It's getting quite the head start on an important clinical trial.
Kymera Jumps 17% on Early Enrollment Completion in Skin Disease Study
KYMR stock soars 17% as investor optimism was lifted following early enrollment completion in mid-stage AD study, moving KT-621 top-line data to year-end 2026.
Strength Seen in Kymera Therapeutics (KYMR): Can Its 16.6% Jump Turn into More Strength?
Kymera Therapeutics (KYMR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
KYMR Stock Clocks Best Day In Over 6 Months On Advancing Eczema Trial Timeline
Kymera said that it finished enrolling patients nearly six months ahead of schedule in a mid-stage trial for KT-621.
Is Kymera Therapeutics The Next Big Rival To Regeneron And Sanofi?
Kymera Therapeutics shares catapulted Thursday after the company wrapped enrollment in an eczema study six months ahead of expectations.